Exploring the mechanism of oxfendazole in inhibiting osteosarcoma-induced osteolysis based on single-cell RNA seqsuencing

Osteosarcoma-associated osteolysis represents a major obstacle in the management of osteosarcoma. Within the osteolytic microenvironment, interactions between osteoclasts and tumor cells facilitate tumor proliferation and metastatic dissemination, and contribute to the development of pathological fractures. However, conventional osteoclast-targeting agents are insufficient to effectively suppress osteosarcoma-driven bone resorption. In this study, single-cell RNA sequencing was performed to identify critical regulators involved in osteoclast differentiation in the context of osteosarcoma. Using the Beyondcell platform, drugs targeting osteoclast-related signaling pathways were screened, and oxfendazole (OFN) was identified as a potential therapeutic candidate, with ANXA2 recognized as a key associated target. In vitro osteoclastogenesis assays and an in vivo tibial orthotopic osteosarcoma model demonstrated that oral administration of OFN via gavage effectively suppressed osteoclast formation and osteolytic activity, as confirmed by micro-CT and histopathological analyses. But OFN alone did not significantly inhibit osteosarcoma growth but effectively reduced osteoclast-mediated osteolysis. In addition, qRT-PCR and immunohistochemistry confirmed that OFN downregulates ANXA2 expression in vitro and in vivo, thereby impairing osteoclast differentiation. Molecular dynamics simulations combined with in-vitro validation further suggested that OFN may interact with the transcription factor ZNF530, leading to reduced ANXA2 transcription. In conclusion, the integration of single-cell RNA sequencing with the Beyondcell algorithm enabled the identification of OFN as a potent candidate agent for osteosarcoma-induced osteolysis. OFN attenuates osteoclastogenesis and bone resorption by suppressing ANXA2 expression. These findings provide preclinical evidence supporting the therapeutic potential of OFN in the treatment of osteosarcoma-associated osteolysis.

Authors

Institutions

Publication Details

Journal
PLoS Computational Biology
Published
2026-11-17
DOI
https://doi.org/10.1371/journal.pcbi.1014828
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploring the mechanism of oxfendazole in inhibiting osteosarcoma-induced osteolysis based on single-cell RNA seqsuencing

Pintian Wang, Yun Liu, Jifeng Miao, Mingxiu Yang et al.
2 links
PLoS Computational Biology
Bone Metabolism and Diseases
article

Exploring the mechanism of oxfendazole in inhibiting osteosarcoma-induced osteolysis based on single-cell RNA seqsuencing

Pintian Wang, Yun Liu, Jifeng Miao, Mingxiu Yang, Shanhang Li, Gejin Wei, Bin-Yuan Ning, Yunhua Lin, Qingjun Wei, Haiyi Quan, Liang Xiong, Jingxin Deng, Wenyu Feng, Fake Meng, Jianming Hu
article en

Abstract

Osteosarcoma-associated osteolysis represents a major obstacle in the management of osteosarcoma. Within the osteolytic microenvironment, interactions between osteoclasts and tumor cells facilitate tumor proliferation and metastatic dissemination, and contribute to the development of pathological fractures. However, conventional osteoclast-targeting agents are insufficient to effectively suppress osteosarcoma-driven bone resorption. In this study, single-cell RNA sequencing was performed to identify critical regulators involved in osteoclast differentiation in the context of osteosarcoma. Using the Beyondcell platform, drugs targeting osteoclast-related signaling pathways were screened, and oxfendazole (OFN) was identified as a potential therapeutic candidate, with ANXA2 recognized as a key associated target. In vitro osteoclastogenesis assays and an in vivo tibial orthotopic osteosarcoma model demonstrated that oral administration of OFN via gavage effectively suppressed osteoclast formation and osteolytic activity, as confirmed by micro-CT and histopathological analyses. But OFN alone did not significantly inhibit osteosarcoma growth but effectively reduced osteoclast-mediated osteolysis. In addition, qRT-PCR and immunohistochemistry confirmed that OFN downregulates ANXA2 expression in vitro and in vivo, thereby impairing osteoclast differentiation. Molecular dynamics simulations combined with in-vitro validation further suggested that OFN may interact with the transcription factor ZNF530, leading to reduced ANXA2 transcription. In conclusion, the integration of single-cell RNA sequencing with the Beyondcell algorithm enabled the identification of OFN as a potent candidate agent for osteosarcoma-induced osteolysis. OFN attenuates osteoclastogenesis and bone resorption by suppressing ANXA2 expression. These findings provide preclinical evidence supporting the therapeutic potential of OFN in the treatment of osteosarcoma-associated osteolysis.

PLoS Computational BiologyVol. 22(11)
Guangxi Medical University (CN), First Affiliated Hospital of GuangXi Medical University (CN), Tumor Hospital of Guangxi Medical University (CN), 303 Hospital of People's Liberation Army (CN), Chinese People's Liberation Army (CN), Chongqing Dazu District People's Hospital (CN)
National Natural Science Foundation of China, Natural Science Foundation of Guangxi Province, Guangxi Medical University, Youth Science Foundation of Guangxi Medical University, Guangxi Key Research and Development Program
Good health and well-being
Bone Metabolism and Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon